The Journal of asthma : official journal of the Association for the Care of Asthma
-
Randomized Controlled Trial Multicenter Study
Translation squared: improving asthma care for high-disparity populations through a safety net practice-based research network.
To assess the effectiveness of an intervention designed to increase compliance with national asthma care guidelines in primary care safety net health centers serving high-disparity patient populations, we conducted a group-randomized controlled trial (seven intervention sites and nine control sites) in federally funded community health centers in eight southeastern states. There were three components involved in the intervention: resources (asthma kits including peak flow meter, MDI spacer device, plus educational materials), training of all health center staff in asthma care guidelines, and tools or templates for practice-level systems change (asthma flow sheets and standing orders). Control group sites received only copies of the national asthma guidelines. ⋯ Clinicians practicing in intervention health centers showed significantly (p < 0.01) greater improvement on some measures than did the control health centers, although postintervention compliance with guidelines was still suboptimal. Disseminating national guidelines is not enough. Providing training and guideline-specific resources, in combination with tools for practice change, improved care significantly even in safety net health centers serving high-disparity patient populations.
-
To determine the net direct medical cost of asthma and to investigate factors influencing costs, a case-control study using data from North Carolina Medicaid (May 1996-April 1998) was used. Comparison subjects were matched 1:1 on age, gender, and race. ⋯ The number of beta-agonist and oral corticosteroid prescriptions was significantly associated with higher costs. The adjusted net cost of asthma to North Carolina Medicaid is approximately 1250 dollars, and the cost of asthma is influenced by beta-agonist and oral corticosteroid exposure.
-
Smoking may have serious consequences for asthmatics. Nevertheless, studies have shown that smoking behavior among asthmatics is similar to or even higher than that of nonasthmatics. Since the relationship between parental smoking and child smoking is well established, this study examined whether the association between parental and child smoking behavior is similar for asthmatic and nonasthmatic adolescents. The impact of parental smoking history was also explored. ⋯ Asthmatic adolescents need to become more aware of the health risks of smoking. Therefore, tailor-made antismoking campaigns are needed at schools to reduce misconceptions among asthmatic adolescents about the risks of smoking. In addition, a personal intervention approach aimed particularly at smoking parents of an asthmatic child, may make them aware of the consequences for their offspring and help them to stop smoking.
-
To study the recent trends in asthma hospitalization and mortality rates by age, gender, and race categories in the United States. ⋯ This study confirms that both asthma hospitalization and mortality rates decreased during the study period and the black to white racial disparity in asthma hospitalization has narrowed for children younger than 10 years of age. For those subjects 10 years and older the racial disparity in hospitalizations narrowed until 2000 but started to widen since then. The widening racial gap in adults is disconcerting and needs further observation to assess its persistence.
-
Randomized Controlled Trial Clinical Trial
Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
Our objective was to compare the efficacy and safety of formoterol (Foradil) delivered via a novel multidose dry powder inhaler (Certihaler) with placebo and albuterol [pressurized metered-dose inhaler (pMDI)], in patients with persistent asthma. After a 2-week run-in phase, 265 patients (13-81 years) previously treated with regular/PRN bronchodilators for persistent asthma were randomized to 12 weeks' double-blind treatment with formoterol 10 microg BID via Certihaler (n = 86), albuterol 180 microg QID via pMDI (n = 88) or placebo (n = 91). The primary efficacy variable was 12-hour AUC of FEV1 after 12 weeks' treatment. ⋯ Asthma symptom scores improved to a similar extent for all treatment groups. Treatment with formoterol via Certihaler was well tolerated. Formoterol 10 microg BID, delivered via the novel Certihaler device, is well tolerated and provides rapid, long-lasting, and clinically superior bronchodilation to placebo and albuterol via pMDI in patients with persistent asthma.